^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    CELLSEARCH®

    Company:
    Menarini
    Type:
    FDA Approved
    Evidence Level:
    Sensitive: C3 – Early Trials

    [PD-L1 expression-Non Small Cell Lung Cancer-PD1 inhibitor]

    Source:
    Clin Lung Cancer
    Test:

    CELLSEARCH®

    Title:
    PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
    Published date:
    03/16/2021
    Excerpt:
    Thirty-nine patients treated with anti-PD-1/PD-L1 agents as second- or third-line therapy were enrolled...Patients were divided into 3 groups: no CTC detectable (CTCnull, n = 15), PD-L1 positive CTC (CTCpos, n = 13), and PD-L1 negative CTC (CTCneg, n = 11)....PD-L1 expression on CTCs is a promising biomarker in patients with NSCLC treated with ICIs.
    DOI:
    10.1016/j.cllc.2021.03.005
    Evidence Level:
    Sensitive: C3 – Early Trials

    [PD-L1 expression-Non Small Cell Lung Cancer-PD-L1 inhibitor]

    Source:
    Clin Lung Cancer
    Test:

    CELLSEARCH®

    Title:
    PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
    Published date:
    03/16/2021
    Excerpt:
    Thirty-nine patients treated with anti-PD-1/PD-L1 agents as second- or third-line therapy were enrolled...Patients were divided into 3 groups: no CTC detectable (CTCnull, n = 15), PD-L1 positive CTC (CTCpos, n = 13), and PD-L1 negative CTC (CTCneg, n = 11)....PD-L1 expression on CTCs is a promising biomarker in patients with NSCLC treated with ICIs.
    DOI:
    10.1016/j.cllc.2021.03.005